Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Takes More Conservative Approach To Quantifying Oncologic Benefit

Executive Summary

FDA seems to be taking a more conservative approach to quantifying oncologics' benefits, based on agency comments during a Sept. 13-14 meeting of its Oncologic Drugs Advisory Committee
Advertisement

Related Content

Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Why Survival Is The Fittest Endpoint For HRPC: The Problem With Pain
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”
Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials
Tarceva Pancreatic Cancer Survival Merits Approval, More Study Of Dosing
Abbott Looks To Xinlay Back-Up Study After Negative Advisory Cmte. Review
Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose
FDA Oncology Drug Reviews Headed By Justice Under Revised Structure
FDA Oncology Drug Reviews Headed By Justice Under Revised Structure

Topics

Advertisement
UsernamePublicRestriction

Register

PS046350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel